Comparison
BPC-157 vs. CJC-1295
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Growth
CAS no.
137525-51-0
no data
Molecular weight
1419.5 g/mol
3647.3 g/mol
Half-life
4 h
144 h
Sequence
GEPPPGKPADDAGLVYADAIFTNSYRKVLGQLSARKLLQDIMSR-DACMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Evidence base
Highest evidence
Animal model
Human trial
Studies
4
3
of which in humans
0
2
Effects recorded
4
3
Open conflicts
2
1
Documented adverse events
2
3